Published in final edited form as:

Physiol Behav. 2012 June 6; 106(3): 332–336. doi:10.1016/j.physbeh.2012.03.020.

Cholinergic modulation of food and drug satiety and withdrawal

Nicole M. Avena^{a,b,*} and Pedro V. Rada^c

^aUniversity of Florida, College of Medicine, Department of Psychiatry, McKnight Brain Institute, Gainesville FL 32610, United States

^bPrinceton University, Department of Psychology, Princeton, NJ 08540, United States

^cUniversidad de Los Andes, School of Medicine, Laboratory of Behavioral Physiology, Merida 5101-A, Venezuela

Abstract

Although they comprise only a small portion of the neurons in the region, cholinergic interneurons in the dorsal striatum appear to play an important role in the regulation of various appetitive behaviors, in part, through their interactions with mesolimbic dopamine (DA) systems. In this review, we describe studies that suggest that the activity of cholinergic interneurons in the nucleus accumbens (NAc) and cholinergic projections to the ventral tegmental area (VTA) affect feeding behavior. In vivo microdialysis studies in rats have revealed that the cessation of a meal is associated with a rise in acetylcholine (ACh) levels in the NAc. ACh activation will suppress feeding, and this is also associated with an increase in synaptic accumulation of ACh. Further, we discuss how, in addition to their role in the ending of a meal, cholinergic interneurons in the NAc play an integral role in the cessation of drug use. Another cholinergic system involved in different aspects of appetitive behavior is the projection from the pedunculopontine nuclei directly to the VTA. Activation of this system enhances behaviors through activation of the mesolimbic DA system, and antagonism of ACh receptors in the VTA can reduce drug self-administration. Finally, we discuss the role of accumbens ACh in both drug and palatable food withdrawal. Studies reveal that accumbens ACh is increased during withdrawal from several different drugs of abuse (including cocaine, nicotine and morphine). This rise in extracellular levels of ACh, coupled with a decrease in extracellular levels of DA, is believed to contribute to an aversive state, which can manifest as behaviors associated with drug withdrawal. This theory has also been applied to studies of overeating and/or “food addiction,” and the findings suggest a similar imbalance in DA/ACh levels, which is associated with behavioral indications of drug-like withdrawal. In summary, cholinergic neurons play an important role in the modulation of both food and drug intake, as well as the aversive aspects of food- and drug-related addictive behaviors.

Keywords

Acetylcholine; Drug use; Feeding; Nucleus accumbens; Satiety; Ventral tegmental area; Withdrawal

1. Introduction

Food intake and drug use have been shown to activate common brain systems, which underlie the reinforcing aspects of these behaviors. The mesolimbic dopamine (DA) system has received a lot of attention with regard to studies of the common reinforcing nature of food and drugs of abuse [1–3]. While DA clearly has an important role, other neurotransmitters have recently begun to receive more attention as primary contributors to the regulation of food and drug intake. In this paper, we will focus on the distinct role that cholinergic neurons have in food and drug ingestion, particularly with regard to their unique contributions to the cessation of food and drug intake, as well as their role in aversive aspects that can ensue following overeating or drug use. Moreover, there is a relationship between DA and cholinergic functions in reward-related brain regions that has been reviewed elsewhere [4–6], and a theory has been proposed that the balance of these neurotransmitter levels in the ventral striatum plays a role in motivated behaviors [5,6], much like the theory that exists regarding the role of the balance of DA and ACh in the dorsal striatum in the control of locomotor activity [7].

2. Mesolimbic ACh projections and inputs

Cholinergic neurons exist in multiple brain regions and activation of their receptors has important roles in many different brain processes and behaviors. In particular, ACh pathways have become interesting to study within the context of reward. As shown in Fig. 1, two major ACh projections innervate key components of the reward system. There is a forebrain projection from the nucleus basalis magnocellularis that provides input to the hippocampus and amygdala. While this pathway is generally implicated in degenerative aspects associated with Parkinson's and Alzheimer's diseases [8], it can also be associated with the learning and memory components of drug addiction [9]. There is also a hindbrain projection of ACh neurons from mesopontine cell groups (Ch 5, 6, pedunculopontine tegmental and laterodorsal tegmental nuclei) directly to the VTA, where they modulate the activity of DA neurons that innervate the NAc [10–13]. Finally, cholinergic interneurons exist in the NAc, where they comprise less than 1% of the neurons in this area, but are the sole direct cholinergic input to this region [14]. As a result, the NAc receives cholinergic input via activation of DA neurons in the VTA, as well as local influence by these cholinergic interneurons.

Of particular note is the fact that these cholinergic interneurons have an important role in the output projections from the NAc to multiple brain regions. Based on the literature and research described below, we propose that these output pathways may have distinct roles in promoting either satiety or appetite, depending on their specific co-transmitters [5]. The opioid peptide dynorphin is a co-transmitter in one GABA-output pathway and enkephalin is a co-transmitter on the other main GABA output pathway [15]. It is proposed that DA promotes appetite or satiety through activation of a select GABA output pathway and cholinergic activation of these pathways via muscarinic receptors.

2.1. Accumbens cholinergic activity modulates the cessation of feeding

The cessation of food intake is often considered in terms of gut–brain communications [16,17]. Indeed, vagal inputs to the brain and hormones that are released by gastric distention have powerful control over whether an animal will eat a meal or whether it will refrain from feeding [18,19]. Orexigenic and anorexigenic neurotransmitters have important roles in multiple brain regions and their specific roles can often depend on their location in the brain. In this section, we focus on the specific effect that ACh neurons and receptors, primarily in the NAc, have on food intake and satiety.

A lot of the information that has been ascertained regarding cholinergic regulation of feeding behavior has come from in vivo microdialysis studies. For example, there is survival value in refraining from eating certain foods, such as in the case of conditioned taste aversion. It has been shown that a conditioned taste aversion can increase extracellular ACh levels in the NAc [20], and conversely, infusion or local administration of the cholinergic agonist neostigmine can induce a conditioned taste aversion [21]. This suggests that inhibition of feeding behavior is associated with a rise in extracellular levels of ACh in the NAc. Further, microdialysis studies also reveal that there is an increase in extracellular levels of ACh in the NAc at the end of a meal [22]. When a meal is prolonged, such as in the case of a binge meal, the rise in extracellular levels of ACh is delayed, and mimics the time course of an exaggerated meal [23]. This delay in the rise of ACh may be related to a delay in satiety that could occur as a result of binge eating. Further support for the theory that increased extracellular levels of accumbens ACh are associated with the cessation of feeding comes from data showing that when rats binge eat sugar while at a reduced body weight, or when they are sham fed sucrose using a gastric cannula, accumbens ACh is blunted [24,25] (Fig. 2). Thus, in situations in which it would be physiologically advantageous for the animal to continue to eat, such as when they are underweight or not retaining the food that is consumed, ACh levels in the NAc are not increased. Perhaps ACh levels serve as a signal to regulate intake of food.

Behavioral studies support the theory that increasing levels of accumbens ACh can promote satiety. When rats are perfused with the indirect cholinergic agonist neostigmine into the NAc, they stop feeding (but continue to drink water normally) [4]. We have also found this effect, as shown in Fig. 3. Sprague–Dawley rats that were food deprived for 20 h were bilaterally microinjected in the NAc with neostigmine. Following the injection, rats were offered chow during the dark cycle. Food intake in the next 3 h decreased dose-dependently in neostigmine-injected rats compared with Ringer-injected control rats (100 mM, $n=10$; 500 μ M, $n=5$; 1000 μ M, $n=5$ and Ringer's solution, $n=5$; $p<0.01$). This finding was cross-validated by infusing neostigmine (1 mM) using reverse dialysis in non-food deprived rats during the dark cycle. In these rats, neostigmine inhibited food intake, while the control animals infused with Ringer's solution ate steadily over 4 h (1 mM, $n=8$; Ringer's solution, $n=6$; $p<0.03$). Together, these results suggest that increased extracellular ACh in the NAc can inhibit feeding. Thus, by promoting ACh levels in the synapse, food intake is attenuated.

It is important to consider that whenever feeding behavior decreases there is always the possibility that this is the result of malaise rather than satiety. In fact, as described above, we know that neostigmine injected in the NAc can induce a conditioned taste aversion [21].

However, the above-mentioned effects with neostigmine appear to be specific to reducing food intake that is not a result of malaise, as shown by water intake not being affected by neostigmine [4]. Further, additional studies support the idea that the promotion of ACh produces a food-specific effect. For example, systemic injection of appetite-suppressing drugs (D-fenfluramine+phentramine) also increases ACh in the accumbens [26].

Other studies suggest that food intake can be promoted by depleting ACh via local injection of the selective cholinergic neurotoxin ethylcholine aziridinium mustard (AF64A) into the NAc. In an acute (1 wk) feeding test, rats that were given this lesion showed a 2-fold increase in food intake [4]. Interestingly, despite this increase in food intake, rats with AF64A lesions in the NAc showed a significant and lasting lag in body weight gain in comparison to the sham-operated controls [27]. Thus, there may be some compensatory mechanisms that occurs when ACh in the accumbens is ablated, which results in rats maintaining a less-than-normal body weight in the long term.

Work by Ann Kelly and her colleagues suggests that ACh receptor antagonism (not agonism) can promote satiety [28]. They find that scopolamine, a pan-antagonist for postsynaptic and presynaptic muscarinic receptors, reduces intake of high-fat food as well as lever pressing for food [29]. However, it should be noted that since scopolamine also blocks the presynaptic M2 autoreceptors on ACh neurons, blocking them increases the extracellular levels of ACh [30]. Thus, the antagonism of the muscarinic receptors with scopolamine might be inducing satiety by increasing extracellular levels of ACh, which could be acting on available muscarinic receptors or through an unknown mechanism to promote satiety. Thus, the exact role of muscarinic receptor mediation in feeding behavior is debatable, and further studies are needed in order to clarify the mechanism of action for the behaviors that have been observed.

In addition to the activity of cholinergic interneurons in the NAc, cholinergic influence in the hypothalamus also appears to participate in the regulation of food intake. This has been shown indirectly by the orexigenic peptide galanin in the hypothalamus lowering extracellular levels of ACh in the NAc [31]. Further, norepinephrine, which in the paraventricular nucleus of the hypothalamus can stimulate food intake, also reduces extracellular levels of ACh in the NAc [32]. More recent studies suggest that cholinergic nicotinic receptors in the hypothalamus activate pro-opiomelanocortin neurons, which subsequently activate melanocortin 4 receptors that are critical for nicotine-induced decreases in food intake in mice [33].

2.2. Cholinergic activity can influence drug intake

As discussed above, increased levels of ACh in the NAc are associated with food satiety, and the activation of specific receptors seems to be important in facilitating this effect, although more research is needed to fully understand the exact mechanisms through which this occurs. The literature suggests that there are overlaps in brain mechanisms that are associated with various appetitive behaviors, including those seen in some types of excessive feeding behaviors (such as overeating or binge eating), and drug use. In order to discuss the overlaps that may exist between overeating and drug addiction as they relate to ACh, in this section, we will very briefly discuss the effects that cholinergic neurons have on

the intake of drugs of abuse. For more comprehensive reviews on this topic, see Williams and Adinoff [34] and Sofuogu and Mooney [35].

Much like the topic of feeding, data are emerging to help disentangle the complicated neurocircuitry and receptor subtype roles in aspects of drug addiction. Different lines of research suggest a fundamental role for accumbens cholinergic interneurons in drug reward. Systemic injection of acetylcholinesterase inhibitors, which serve as indirect ACh agonists by inhibiting ACh enzymatic degradation, can decrease cocaine self-administration in monkeys [36], block heroin seeking [37], and prevent cocaine and heroin conditioned place preference in rats [38], as well as preference for cocaine in mice [39]. Other studies have assessed the specific role of cholinergic interneurons in the NAc in the development of cocaine conditioning. Not only are these neurons activated by cocaine, but silencing of these neurons during cocaine exposure blocks cocaine conditioning in rats [40].

Perhaps the most well-known example of cholinergic regulation of drug intake comes from studies of nicotine. Smoking decreases appetite and many smokers report that they smoke to control their body weight [41]. Nicotine is an agonist of nicotinic ACh receptors [42]. Activation of nicotinic receptors on both NAc interneurons and/or on cell bodies that exist in the VTA increases DA in the NAc [43,44], and this release of DA is associated with the potent reinforcing value of nicotinic agonists. Blockade of the nicotinic cholinergic receptors in the VTA (using the antagonist mecamylamine) prevents DA release in response to systemic cocaine [4], which normally increases extracellular levels of ACh in the VTA. This suggests that psychostimulants may require cholinergic input on DA neurons in the VTA. Thus, nicotinic receptors expressed in the VTA are necessary for the effects of systemic nicotine on DA neuron activity and DA-dependent behaviors, such as locomotion, reinforcement, and behavioral sensitization [45,46]. Activation of muscarinic receptors can also influence drug self-administration. The mixed muscarinic agonist oxotremorine inhibits self-administration and breakpoint for cocaine [4,47]. Further, local injection of the muscarinic M2 autoreceptor antagonist oxotremorine-sesquifumarate into the lateral dorsal tegmental nucleus reduces motivation for food as well as cocaine self-administration, suggesting that inactivation of cholinergic input to the VTA is needed for these behaviors [4]. However, recent studies suggest that M4 receptors also may have a critical role in the facilitation of drug intake; M4 receptor knockout mice show increased intake of cocaine [48].

Thus, several studies highlight the important role of cholinergic input in the development of drug addiction [49]. Based on this work, it has been suggested that the cholinergic system be targeted in treating nicotine and other drug addiction [34,35,45]. Preclinical experiments support this idea. For example, when the nicotinic antagonist mecamylamine is added to the solution of cocaine, rats still consume it, but do not progressively escalate their intake of it [4,50]. Since escalation of intake is associated with the development of dependence, antagonism of nicotinic receptors might attenuate the development of dependence on cocaine. Furthermore, cholinesterase inhibitors have been used to attenuate the subjective effects of methylphenidate [51] and amphetamine [52].

2.3. ACh activity is modulated by food and drug withdrawal

In light of the recent publicity surrounding the obesity epidemic, the concept of “food addiction” has been popularized. In particular, clinical accounts of “food addiction” have been the topic of many books and popular diet programs [53–57]. In these accounts, people describe symptoms of withdrawal when they deprive themselves of highly-palatable foods, and these feelings are combined with food craving, particularly for carbohydrates, chocolate, and sugar, which can trigger impulsive eating. This leads to a vicious cycle of self-medication with foods that, for some people, may result in obesity or an eating disorder. Although food addiction has been popular in the media and proposed to be based on brain neurochemistry [58,59], this phenomenon has only recently been systematically studied in the laboratory.

The concept of addiction in animals and the means by which it can be studied are rooted in the classical drug addiction literature. There are known overlaps that exist in brain reward regions that are activated by food and drugs of abuse [1,3,60,61]. We have used models that were developed with rats for studying drug dependence and adapted them to test for signs of food dependence. In our animal model, rats are food deprived daily for 12 h, then are given food and a sugar solution (25% glucose or 10% sucrose) after a delay of 4 h into their normal circadian-driven active period to stimulate a large meal (for review, see [62]). As a result, rats drink the sugar solution copiously (i.e., they binge), especially when it first becomes available each day, and they ultimately enter a state that resembles drug dependence on several dimensions [1]. Clinical studies have also been conducted using scales and brain imaging, lending support to the findings in animal models that suggest that some foods can produce behaviors and brain changes that resemble drug addiction (for review, see [60,63])

Together, this clinical and preclinical work has led to the suggestion that excessive intake of palatable food, which can sometimes result in obesity, can lead to a dependent-like state [1,63,64]. While in terms of neurochemistry, the majority of the work in this region has focused on the mesolimbic DA system [23,65–68], here we will review data that has come from our group, which shows similarities that exist between drug use and binge intake of palatable food with regard to accumbens ACh.

As mentioned above, the balance between DA and ACh in the NAc has been suggested to have a role in aspects of reinforcement, with drugs of abuse increasing extracellular levels of DA while ACh is relatively low [5]. However, in cases of withdrawal, the opposite balance is seen. Morphine dependent rats that are given an opioid antagonist to precipitate withdrawal show a decrease in extracellular levels of DA that is coupled with an increase in ACh [69–71]. This same imbalance of DA/ACh has been shown during withdrawal from other drugs, including alcohol and nicotine [72,73].

Food addiction studies using animal models show that rats that repeatedly overeat palatable foods enter a state in which they show behavioral indications of withdrawal [62,66]. In addition to these behaviors, they show alterations in extracellular levels of ACh in the NAc that are consistent with the findings described above for drugs of abuse. When withdrawal is precipitated with the opioid antagonist naloxone or it emerges spontaneously in response to

fasting (Fig. 4) rats show an increase in the levels of ACh in the NAc that is coupled with an increase in NAC DA. Thus, rats in withdrawal from palatable food appear to show the profile of ACh in the NAc that has been seen in withdrawal from drugs of abuse.

3. Conclusions

Cholinergic influence on mesolimbic systems clearly has a role in the ingestion of both food and drugs of abuse. In this review, we highlight studies that have been conducted to uncover the contribution that ACh makes toward feeding behavior, and we conclude that increased levels of ACh in the NAc act to promote satiety. Cholinergic input, via nicotinic receptor activation, facilitates the intake and perhaps promotes dependence on many different drugs of abuse. Finally, we discuss how both excessive intake of palatable foods and drugs of abuse can result in a state of behavioral withdrawal, which is characterized by relatively lower levels of DA in the NAc, coupled with elevated ACh.

Acknowledgments

We would like to thank Miaoyuan Wang for her assistance with developing the figures, and Miriam Bocarsly for her comments on earlier drafts of the manuscript. Supported by: DA-031230 (NMA), National Eating Disorders Association (NMA), University of Florida (NMA) and Kildehoj-Santini (NMA).

References

1. Avena NM, Rada P, Hoebel BG. Evidence for sugar addiction: behavioral and neurochemical effects of intermittent, excessive sugar intake. *Neurosci Biobehav Rev.* 2008; 32:20–39. [PubMed: 17617461]
2. Volkow ND, Wang GJ, Baler RD. Reward, dopamine and the control of food intake: implications for obesity. *Trends Cogn Sci.* 2011; 15:37–46. [PubMed: 21109477]
3. Wise RA. Role of brain dopamine in food reward and reinforcement. *Philos Trans R Soc Lond B Biol Sci.* 2006; 361:1149–58. [PubMed: 16874930]
4. Mark GP, Shabani S, Dobbs LK, Hansen ST. Cholinergic modulation of mesolimbic dopamine function and reward. *Physiol Behav.* 2011; 104:76–81. [PubMed: 21549724]
5. Hoebel BG, Avena NM, Rada P. Accumbens dopamine–acetylcholine balance in approach and avoidance. *Curr Opin Pharmacol.* 2007; 7:617–27. [PubMed: 18023617]
6. Threlfell S, Cragg SJ. Dopamine signaling in dorsal versus ventral striatum: the dynamic role of cholinergic interneurons. *Front Syst Neurosci.* 2011; 5:11. [PubMed: 21427783]
7. McGeer PL, McGeer EG. Chemistry of mood and emotion. *Annu Rev Psychol.* 1980; 31:273–307. [PubMed: 6102450]
8. Schliebs R, Arendt T. The cholinergic system in aging and neuronal degeneration. *Behav Brain Res.* 2011; 221:555–63. [PubMed: 21145918]
9. See RE, McLaughlin J, Fuchs RA. Muscarinic receptor antagonism in the basolateral amygdala blocks acquisition of cocaine-stimulus association in a model of relapse to cocaine-seeking behavior in rats. *Neuroscience.* 2003; 117:477–83. [PubMed: 12614687]
10. Yeomans JS. Role of tegmental cholinergic neurons in dopaminergic activation, antimuscarinic psychosis and schizophrenia. *Neuropsychopharmacology.* 1995; 12:3–16. [PubMed: 7766284]
11. Yeomans J, Baptista M. Both nicotinic and muscarinic receptors in ventral tegmental area contribute to brain-stimulation reward. *Pharmacol Biochem Behav.* 1997; 57:915–21. [PubMed: 9259024]
12. Picciotto MR, Corrigall WA. Neuronal systems underlying behaviors related to nicotine addiction: neural circuits and molecular genetics. *J Neurosci.* 2002; 22:3338–41. [PubMed: 11978809]

13. Zanetti L, Picciotto MR, Zoli M. Differential effects of nicotinic antagonists perfused into the nucleus accumbens or the ventral tegmental area on cocaine-induced dopamine release in the nucleus accumbens of mice. *Psychopharmacology (Berl)*. 2007; 190:189–99. [PubMed: 17061109]
14. Zhou FM, Wilson CJ, Dani JA. Cholinergic interneuron characteristics and nicotinic properties in the striatum. *J Neurobiol*. 2002; 53:590–605. [PubMed: 12436423]
15. Redgrave P, et al. Goal-directed and habitual control in the basal ganglia: implications for Parkinson's disease. *Nat Rev Neurosci*. 2010; 11:760–72. [PubMed: 20944662]
16. Zheng H, Lenard NR, Shin SC, Berthoud HR. Appetite control and energy balance regulation in the modern world: reward-driven brain overrides repletion signals. *Int J Obes (Lond)*. 2009; 33(Suppl 2):S8–S13. [PubMed: 19528982]
17. Moran TH. Gut peptides in the control of food intake. *Int J Obes (Lond)*. 2009; 33(Suppl 1):S7–S10. [PubMed: 19363513]
18. Kral JG, Paez W, Wolfe BM. Vagal nerve function in obesity: therapeutic implications. *World J Surg*. 2009; 33:1995–2006. [PubMed: 19618240]
19. Olszewski PK, Klockars A, Schioth HB, Levine AS. Oxytocin as feeding inhibitor: maintaining homeostasis in consummatory behavior. *Pharmacol Biochem Behav*. 2010; 97:47–54. [PubMed: 20595062]
20. Mark GP, Weinberg JB, Rada PV, Hoebel BG. Extracellular acetylcholine is increased in the nucleus accumbens following the presentation of an aversively conditioned taste stimulus. *Brain Res*. 1995; 688:184–8. [PubMed: 8542305]
21. Taylor KM, Mark GP, Hoebel BG. Conditioned taste aversion from neostigmine or methyl-naloxonium in the nucleus accumbens. *Physiol Behav*. 2011; 104:82–6. [PubMed: 21549734]
22. Mark GP, Rada P, Pothos E, Hoebel BG. Effects of feeding and drinking on acetylcholine release in the nucleus accumbens, striatum, and hippocampus of freely behaving rats. *J Neurochem*. 1992; 58:2269–74. [PubMed: 1573406]
23. Rada P, Avena NM, Hoebel BG. Daily bingeing on sugar repeatedly releases dopamine in the accumbens shell. *Neuroscience*. 2005; 134:737–44. [PubMed: 15987666]
24. Avena NM, Rada P, Hoebel BG. Underweight rats have enhanced dopamine release and blunted acetylcholine response in the nucleus accumbens while bingeing on sucrose. *Neuroscience*. 2008; 156:865–71. [PubMed: 18790017]
25. Avena NM, Rada P, Moise N, Hoebel BG. Sucrose sham feeding on a binge schedule releases accumbens dopamine repeatedly and eliminates the acetylcholine satiety response. *Neuroscience*. 2006; 139:813–20. [PubMed: 16460879]
26. Rada PV, Hoebel BG. Supraadditive effect of D-fenfluramine plus phentermine on extracellular acetylcholine in the nucleus accumbens: possible mechanism for inhibition of excessive feeding and drug abuse. *Pharmacol Biochem Behav*. 2000; 65:369–73. [PubMed: 10683475]
27. Hajnal A, Szekely M, Galosi R, Lenard L. Accumbens cholinergic interneurons play a role in the regulation of body weight and metabolism. *Physiol Behav*. 2000; 70:95–103. [PubMed: 10978483]
28. Perry ML, Baldo BA, Andrzejewski ME, Kelley AE. Muscarinic receptor antagonism causes a functional alteration in nucleus accumbens mu-opiate-mediated feeding behavior. *Behav Brain Res*. 2009; 197:225–9. [PubMed: 18761381]
29. Will MJ, Pratt WE, Kelley AE. Pharmacological characterization of high-fat feeding induced by opioid stimulation of the ventral striatum. *Physiol Behav*. 2006; 89:226–34. [PubMed: 16854442]
30. Chau DT, Rada P, Kosloff RA, Taylor JL, Hoebel BG. Nucleus accumbens muscarinic receptors in the control of behavioral depression: antidepressant-like effects of local M1 antagonist in the Porsolt swim test. *Neuroscience*. 2001; 104:791–8. [PubMed: 11440810]
31. Rada P, Mark GP, Hoebel BG. Galanin in the hypothalamus raises dopamine and lowers acetylcholine release in the nucleus accumbens: a possible mechanism for hypothalamic initiation of feeding behavior. *Brain Res*. 1998; 798:1–6. [PubMed: 9666056]
32. Hajnal A, Mark GP, Rada PV, Lenard L, Hoebel BG. Norepinephrine microinjections in the hypothalamic paraventricular nucleus increase extracellular dopamine and decrease acetylcholine in the nucleus accumbens: relevance to feeding reinforcement. *J Neurochem*. 1997; 68:667–74. [PubMed: 9003054]

33. Mineur YS, et al. Nicotine decreases food intake through activation of POMC neurons. *Science*. 2011; 332:1330–2. [PubMed: 21659607]
34. Williams MJ, Adinoff B. The role of acetylcholine in cocaine addiction. *Neuropsychopharmacology*. 2008; 33:1779–97. [PubMed: 17928814]
35. Sofuoglu M, Mooney M. Cholinergic functioning in stimulant addiction: implications for medications development. *CNS Drugs*. 2009; 23:939–52. [PubMed: 19845415]
36. de la Garza R, Johanson CE. Effects of haloperidol and physostigmine on self-administration of local anesthetics. *Pharmacol Biochem Behav*. 1982; 17:1295–9. [PubMed: 7163358]
37. Zhou W, et al. Role of acetylcholine transmission in nucleus accumbens and ventral tegmental area in heroin-seeking induced by conditioned cues. *Neuroscience*. 2007; 144:1209–18. [PubMed: 17184925]
38. Hikida T, Kitabatake Y, Pastan I, Nakanishi S. Acetylcholine enhancement in the nucleus accumbens prevents addictive behaviors of cocaine and morphine. *Proc Natl Acad Sci U S A*. 2003; 100:6169–73. [PubMed: 12721372]
39. Takamatsu Y, Yamanishi Y, Hagino Y, Yamamoto H. Differential effects of donepezil on methamphetamine and cocaine dependencies. *Ann N Y Acad Sci*. 2006; 1074:418–26. [PubMed: 17105940]
40. Witten IB, et al. Cholinergic interneurons control local circuit activity and cocaine conditioning. *Science*. 2010; 330:1677–81. [PubMed: 21164015]
41. Edge PJ, Gold MS. Drug withdrawal and hyperphagia: lessons from tobacco and other drugs. *Curr Pharm Des*. 2011; 17:1173–9. [PubMed: 21492091]
42. Mansvelder HD, McGehee DS. Cellular and synaptic mechanisms of nicotine addiction. *J Neurobiol*. 2002; 53:606–17. [PubMed: 12436424]
43. Mifsud JC, Hernandez L, Hoebel BG. Nicotine infused into the nucleus accumbens increases synaptic dopamine as measured by in vivo microdialysis. *Brain Res*. 1989; 478:365–7. [PubMed: 2924134]
44. Schilstrom B, Svensson HM, Svensson TH, Nomikos GG. Nicotine and food induced dopamine release in the nucleus accumbens of the rat: putative role of alpha7 nicotinic receptors in the ventral tegmental area. *Neuroscience*. 1998; 85:1005–9. [PubMed: 9681941]
45. Gotti C, et al. Nicotinic acetylcholine receptors in the mesolimbic pathway: primary role of ventral tegmental area alpha6beta2* receptors in mediating systemic nicotine effects on dopamine release, locomotion, and reinforcement. *J Neurosci*. 2010; 30:5311–25. [PubMed: 20392953]
46. Degoulet M, Rostain JC, Abiraini JH, Davis HN. Short-term development of behavioral sensitization to amphetamine requires N-methyl-D-aspartate- and nicotinic-dependent mechanisms in the nucleus accumbens. *Addict Biol*. 2011 [epub ahead of print].
47. Mark GP, et al. Injection of oxotremorine in nucleus accumbens shell reduces cocaine but not food self-administration in rats. *Brain Res*. 2006; 1123:51–9. [PubMed: 17045970]
48. Schmidt LS, et al. Increased cocaine self-administration in M4 muscarinic acetylcholine receptor knockout mice. *Psychopharmacology (Berl)*. 2011; 216:367–78. [PubMed: 21373792]
49. Mansvelder HD, De Rover M, McGehee DS, Brussaard AB. Cholinergic modulation of dopaminergic reward areas: upstream and downstream targets of nicotine addiction. *Eur J Pharmacol*. 2003; 480:117–23. [PubMed: 14623355]
50. Hansen ST, Mark GP. The nicotinic acetylcholine receptor antagonist mecamylamine prevents escalation of cocaine self-administration in rats with extended daily access. *Psychopharmacology (Berl)*. 2007; 194:53–61. [PubMed: 17530475]
51. Janowsky DS, el-Yousef MK, Davis JM, Sekerke HJ. Antagonistic effects of physostigmine and methylphenidate in man. *Am J Psychiatry*. 1973; 130:1370–6. [PubMed: 4754682]
52. De La Garza R II, Mahoney JJ III, Culbertson C, Shoptaw S, Newton TF. The acetylcholinesterase inhibitor rivastigmine does not alter total choices for methamphetamine, but may reduce positive subjective effects, in a laboratory model of intravenous self-administration in human volunteers. *Pharmacol Biochem Behav*. 2008; 89:200–8. [PubMed: 18207225]
53. Appleton, N. *Lick the Sugar Habit*. Santa Monica: Nancy Appleton; 1996.
54. Rufus, EB. *Sugar Addiction: a Step-by-step Guide to Overcoming Sugar Addiction*. Bloomington, IN: AuthorHouse; 2004.

55. DesMaisons, K. *Your Last Diet!: the Sugar Addict's Weight-loss Plan*. Toronto: Random House; 2001.
56. Katherine, A. *Anatomy of a Food Addiction: an Effective Program to Overcome Compulsive Eating*. Carlsbad: Gurze Books; 1996.
57. Bennett, C.; Sinatra, S. *Sugar Shock!*. New York: Penguin Group; 2007.
58. Hoebel BG, Hernandez L, Schwartz DH, Mark GP, Hunter GA. Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during ingestive behavior. Theoretical and clinical implications. *Ann N Y Acad Sci*. 1989; 575:171–91. (discussion 192–3). [PubMed: 2699187]
59. Le Magnen, J. A role for opiates in food reward and food addiction. In: Capaldi, PT., editor. *Taste, Experience, and Feeding*. Washington, DC: APA; 1990. p. 241–52.
60. Avena NM, Bocarsly ME, Hoebel BG, Gold MS. Overlaps in the nosology of substance abuse and overeating: the translational implications of “food addiction”. *Curr Drug Abuse Rev*. 2011; 4:133–9. [PubMed: 21999687]
61. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Baler R. Food and drug reward: overlapping circuits in human obesity and addiction. *Curr Top Behav Neurosci*. 2011 [epub ahead of print].
62. Avena NM, Bocarsly ME, Rada P, Kim A, Hoebel BG. After daily bingeing on a sucrose solution, food deprivation induces anxiety and accumbens dopamine/acetylcholine imbalance. *Physiol Behav*. 2008; 94:309–15. [PubMed: 18325546]
63. Gearhardt AN, Davis C, Kuschner R, Brownell KD. The addiction potential of hyperpalatable foods. *Curr Drug Abuse Rev*. 2011; 4:140–5. [PubMed: 21999688]
64. Avena NM, Rada P, Hoebel BG. Sugar and fat bingeing have notable differences in addictive-like behavior. *J Nutr*. 2009; 139:623–8. [PubMed: 19176748]
65. Johnson PM, Kenny PJ. Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats. *Nat Neurosci*. 2010; 13:635–41. [PubMed: 20348917]
66. Colantuoni C, et al. Evidence that intermittent, excessive sugar intake causes endogenous opioid dependence. *Obes Res*. 2002; 10:478–88. [PubMed: 12055324]
67. Colantuoni C, et al. Excessive sugar intake alters binding to dopamine and mu-opioid receptors in the brain. *Neuroreport*. 2001; 12:3549–52. [PubMed: 11733709]
68. Spangler R, Wittkowski KM, Goddard NL, Avena NM, Hoebel BG, Leibowitz SF. Opiate-like effects of sugar on gene expression in reward areas of the rat brain. *Brain Res Mol Brain Res*. 2004; 124:134–42. [PubMed: 15135221]
69. Rada P, Mark GP, Pothos E, Hoebel BG. Systemic morphine simultaneously decreases extracellular acetylcholine and increases dopamine in the nucleus accumbens of freely moving rats. *Neuropharmacology*. 1991; 30:1133–6. [PubMed: 1758589]
70. Rada P, Pothos E, Mark GP, Hoebel BG. Microdialysis evidence that acetylcholine in the nucleus accumbens is involved in morphine withdrawal and its treatment with clonidine. *Brain Res*. 1991; 561:354–6. [PubMed: 1802350]
71. Rada PV, Mark GP, Taylor KM, Hoebel BG. Morphine and naloxone, i.p. or locally, affect extracellular acetylcholine in the accumbens and prefrontal cortex. *Pharmacol Biochem Behav*. 1996; 53:809–16. [PubMed: 8801582]
72. Rada P, Jensen K, Hoebel BG. Effects of nicotine and mecamylamine-induced withdrawal on extracellular dopamine and acetylcholine in the rat nucleus accumbens. *Psychopharmacology (Berl)*. 2001; 157:105–10. [PubMed: 11512050]
73. Rada P, Johnson DF, Lewis MJ, Hoebel BG. In alcohol-treated rats, naloxone decreases extracellular dopamine and increases acetylcholine in the nucleus accumbens: evidence of opioid withdrawal. *Pharmacol Biochem Behav*. 2004; 79:599–605. [PubMed: 15582668]

Fig. 1. Schematic depicting regions of the brain with cholinergic influence on feeding and drug reward and withdrawal. Solid lines represent ACh projection, and broke lines represent DA projections. FC = frontal cortex; HPP=hippocampus; NAC = nucleus accumbens, NMB = nucleus basalis magnocellularis; Amy = amygdala; VTA = ventral tegmental area; Ch 5,6 = pedunculopontine tegmental and laterodorsal tegmental nuclei.

Fig. 2.

Rats with gastric fistulas were either real-fed (drain-valve sealed) or sham-fed (drain-valve open) 10% sucrose (marked with black bars) for 1 h. ACh rises during the meals in real-fed animals (open squares), but fails to rise during sham meals (filled squares). [‡] $p < 0.05$.

Adapted from [25].

Fig. 3.

The cholinergic agonist neostigmine injected bilaterally in the NAc shell causes a dose-related decrease in intake of standard rodent chow. * $p < 0.05$.

Fig. 4.

Extracellular ACh in the NAc following 24 and 36 h of fasting. Extracellular ACh was significantly increased in the 12-h binge sugar+chow group (which also shows behavioral signs of opiate-like withdrawal and other signs of addiction to the sugar) at the 36 h fasting point compared with both control groups. * $p < 0.05$ compared with both binge (12-h) chow and ad libitum chow.

Reproduced with permission from [62].